Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
CDC Shake-Up Sparks Vaccine Policy Clash Between RFK Jr. and Susan Monarez 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
On Tuesday, Pfizer announced its decision to donate the rights of royalties from sales of the cancer drug Bavencio to the American Association for Cancer Research. This move comes as a response to concerns raised by US antitrust regulators regarding Pfizer's proposed $43 billion acquisition of Seagen.
After receiving all necessary regulatory approvals, the deal is set to close on Thursday, nearly nine months since its initial announcement, as per Reuters.
Reorganization and Leadership Changes
Pfizer plans to establish a separate division dedicated to cancer drugs as part of its efforts to streamline operations. Additionally, the company intends to split its remaining commercial business into two divisions, one focused on the United States and the other on the rest of the world.
Chief Commercial Officer Angela Hwang will step down, allowing Aamir Malik to assume the US unit's commercial chief role. In the international unit, Alexandre de Germay will take on the position of commercial chief.
Sales and Financial Outlook
Bavencio, a vital cancer drug, generated sales amounting to $271 million for Pfizer in 2022. This acquisition of Seagen, with its targeted cancer therapies, comes at a crucial time for Pfizer. Facing the anticipated decline in COVID-related sales and the looming threat of generic competition for its top-selling drugs, Pfizer seeks to bolster its oncology portfolio and maintain its position as a leader in the pharmaceutical industry.
However, the acquisition faced scrutiny from the US Federal Trade Commission (FTC) earlier this year. In July, the FTC requested more information on the deal from both parties involved, seeking to ensure compliance with antitrust laws. Despite this additional hurdle, Pfizer remains committed to moving forward with the acquisition and closing the deal as planned.
Business Times noted that Seagen, based in Washington, is recognized as a pioneer of antibody-drug conjugates. These innovative treatments function like "guided missiles," specifically designed to target and destroy cancer cells while sparing healthy cells. With this cutting-edge technology and expertise, Seagen contributes to advancing more effective and targeted cancer therapies.
Photo: Pfizer Newsroom
